Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC - ScienceDirect
ADAURA Update Supports Strong Disease-Free Survival Benefit of Osimertinib in Early-Stage, EGFR-Mutated NSCLC
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Frontiers | Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection - ScienceDirect
Asco 2020 – Tagrisso shows what early targeting can do | Evaluate
Efficacy of TAGRISSO® (osimertinib) in Resectable EGFRm NSCLC
ADAURA: Phase III, Double‐blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation‐positive Early‐stage NSCLC After Complete Surgical Resection | Semantic Scholar
ASCO 2020: Results From the Phase 3 ADAURA Trial
Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
Yale Cancer Center Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC < Yale School of Medicine
ADAURA and Selecting Adjuvant Therapy in EGFR Mutant Early-Stage NSCLC
Improving outcomes in the early-stage setting with (neo)adjuvant strategies - memoinOncology
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)
Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons - The Journal of Thoracic and Cardiovascular Surgery
Clinical trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
IJMS | Free Full-Text | Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
A) Overall survival (OS): hazard ratio (HR) of death with chemotherapy... | Download Scientific Diagram
ADAURA Trial Results and NSCLC Treatment Decisions
Overall survival (OS) benefit stratification by MINERVA a Kaplan–Meier... | Download Scientific Diagram
Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC - ILCN.org (ILCN/WCLC)
ASCO 2020: Results From the Phase 3 ADAURA Trial
